TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect.

@article{Yamamoto2005TAS108AN,
  title={TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect.},
  author={Yoshiro Yamamoto and Jiro Shibata and Kazuhiko Yonekura and Kouji Sato and Akihiro Hashimoto and Y Aoyagi and Konstanty Wierzba and Shingo Yano and Tetsuji Asao and Aman U. Buzdar and Tadafumi Terada},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2005},
  volume={11 1},
  pages={
          315-22
        }
}
PURPOSE Investigators are currently conducting phase II trials on TAS-108, a novel oral steroidal antiestrogenic agent. The purpose of this study is to investigate the molecular and pharmacologic properties of TAS-108 compared with other antiestrogenic agents such as tamoxifen,raloxifene, and fulvestrant. EXPERIMENTAL DESIGN The antagonistic or agonistic activities of these agents against both estrogen receptors (ER) alpha and beta were compared in the reporter assay systems. Their effects on… CONTINUE READING
2
Twitter Mentions

References

Publications referenced by this paper.
SHOWING 1-10 OF 45 REFERENCES

Endometrial cancer in Clinical Cancer Research 321

B Fisher, JP Costantino, CK Redmond
  • Cancer Research. on October
  • 2005
VIEW 14 EXCERPTS
HIGHLY INFLUENTIAL